Protara Therapeutics Inc (NASDAQ:TARA) has a beta value of 1.68 and has seen 1.11 million shares traded in the last trading session. The company, currently valued at $181.59M, closed the last trade at $5.53 per share which meant it lost -$0.45 on the day or -7.53% during that session. The TARA stock price is -89.51% off its 52-week high price of $10.48 and 73.6% above the 52-week low of $1.46. If we look at the company’s 10-day average daily trading volume, we find that it stood at 12.86 million shares traded. The 3-month trading volume is 2.15 million shares.
The consensus among analysts is that Protara Therapeutics Inc (TARA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.59.
Protara Therapeutics Inc (NASDAQ:TARA) trade information
Sporting -7.53% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the TARA stock price touched $5.53 or saw a rise of 14.26%. Year-to-date, Protara Therapeutics Inc shares have moved 194.92%, while the 5-day performance has seen it change -17.09%. Over the past 30 days, the shares of Protara Therapeutics Inc (NASDAQ:TARA) have changed 114.34%. Short interest in the company has seen 2.74 million shares shorted with days to cover at 14.46.
Protara Therapeutics Inc (TARA) estimates and forecasts
Figures show that Protara Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 116.86% over the past 6 months, with this year growth rate of 16.25%, compared to 16.40% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 39.98% over the past 5 years.
TARA Dividends
Protara Therapeutics Inc is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Protara Therapeutics Inc (NASDAQ:TARA)’s Major holders
Insiders own 6.13% of the company shares, while shares held by institutions stand at 51.11% with a share float percentage of 54.45%. Investors are also buoyed by the number of investors in a company, with Protara Therapeutics Inc having a total of 45.0 institutions that hold shares in the company. The top two institutional holders are OPALEYE MANAGEMENT INC. with over 2.3 million shares worth more than $5.3 million. As of 2024-06-30, OPALEYE MANAGEMENT INC. held 20.1758% of shares outstanding.
The other major institutional holder is RA CAPITAL MANAGEMENT, L.P., with the holding of over 1.9 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.95 million and represent 16.6361% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . As of Sep 30, 2024 , the former fund manager holds about 2.99% shares in the company for having 616.3 shares of worth $3.41 million while later fund manager owns 140.67 shares of worth $0.78 million as of Sep 30, 2024 , which makes it owner of about 0.68% of company’s outstanding stock.
